Haematologica (Jan 2017)
Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group
- Holly L. Geyer,
- Heidi Kosiorek,
- Amylou C. Dueck,
- Robyn Scherber,
- Stefanie Slot,
- Sonja Zweegman,
- Peter AW te Boekhorst,
- Zhenya Senyak,
- Harry C. Schouten,
- Federico Sackmann,
- Ana Kerguelen Fuentes,
- Dolores Hernández-Maraver,
- Heike L. Pahl,
- Martin Griesshammer,
- Frank Stegelmann,
- Konstanze Döhner,
- Thomas Lehmann,
- Karin Bonatz,
- Andreas Reiter,
- Francoise Boyer,
- Gabriel Etienne,
- Jean-Christophe Ianotto,
- Dana Ranta,
- Lydia Roy,
- Jean-Yves Cahn,
- Claire N. Harrison,
- Deepti Radia,
- Pablo Muxi,
- Norman Maldonado,
- Carlos Besses,
- Francisco Cervantes,
- Peter L. Johansson,
- Tiziano Barbui,
- Giovanni Barosi,
- Alessandro M. Vannucchi,
- Chiara Paoli,
- Francesco Passamonti,
- Bjorn Andreasson,
- Maria L Ferrari,
- Alessandro Rambaldi,
- Jan Samuelsson,
- Keith Cannon,
- Gunnar Birgegard,
- Zhijian Xiao,
- Zefeng Xu,
- Yue Zhang,
- Xiujuan Sun,
- Junqing Xu,
- Jean-Jacques Kiladjian,
- Peihong Zhang,
- Robert Peter Gale,
- Ruben A. Mesa
Affiliations
- Holly L. Geyer
- Department of Internal Medicine, Mayo Clinic, Scottsdale, AZ, USA
- Heidi Kosiorek
- Section of Biostatistics, Mayo Clinic, Scottsdale, AZ, USA
- Amylou C. Dueck
- Section of Biostatistics, Mayo Clinic, Scottsdale, AZ, USA
- Robyn Scherber
- Oregon Health Sciences University, Portland, OR, USA
- Stefanie Slot
- Department of Hematology, VU University Medical Center, Amsterdam, the Netherlands
- Sonja Zweegman
- Department of Hematology, VU University Medical Center, Amsterdam, the Netherlands
- Peter AW te Boekhorst
- Department of Hematology, Erasmus MC, Rotterdam, the Netherlands
- Zhenya Senyak
- MPN Forum, Ashville, NC, USA
- Harry C. Schouten
- Department of Hematology, MUMC, Maastricht, the Netherlands
- Federico Sackmann
- Fundaleu, Buenos Aires, Argentina
- Ana Kerguelen Fuentes
- Department of Haematology, University Hospital La Paz, Madrid, Spain
- Dolores Hernández-Maraver
- Department of Haematology, University Hospital La Paz, Madrid, Spain
- Heike L. Pahl
- Department of Molecular Hematology, University Hospital Freiburg, Germany
- Martin Griesshammer
- Johannes Wesling Klinikum, Minden, Germany
- Frank Stegelmann
- Department of Internal Medicine III, University Hospital of Ulm, Germany
- Konstanze Döhner
- Department of Internal Medicine III, University Hospital of Ulm, Germany
- Thomas Lehmann
- Hematology Department, University Hospital, Basel, Switzerland
- Karin Bonatz
- Medizinische Klinik, Universitätsmedizin, Mannheim, Germany
- Andreas Reiter
- Medizinische Klinik, Universitätsmedizin, Mannheim, Germany
- Francoise Boyer
- Centre Hospitalier Universitaire, Angers, France
- Gabriel Etienne
- Institut Bergonie, Bordeaux, France
- Jean-Christophe Ianotto
- Centre Hospitalier Universitaire, Brest, France
- Dana Ranta
- Hospitalier Universitaire, Nancy, France
- Lydia Roy
- Centre Hospitalier Universitaire, Poitiers, France
- Jean-Yves Cahn
- Centre Hospitalier Universitaire, Grenoble, France
- Claire N. Harrison
- Department of Haematology, Guy’s and St. Thomas NHS Foundation Trust, London, UK
- Deepti Radia
- Department of Haematology, Guy’s and St. Thomas NHS Foundation Trust, London, UK
- Pablo Muxi
- Unidadde Hematología, Hospital Británico, Montevideo, Uruguay
- Norman Maldonado
- University of Puerto Rico School of Medicine, San Juan, Puerto Rico
- Carlos Besses
- Hematology Department, Hospital del Mar, Barcelona, Spain
- Francisco Cervantes
- Hematology Department, Hospital Clínic, IDIBAPS, University of Barcelona, Spain
- Peter L. Johansson
- Internal Medicine, NU Hospital Organization, Uddevalla, Sweden
- Tiziano Barbui
- Research Foundation (FROM), Hospital Papa Giovanni XXIII, Bergamo, Italy
- Giovanni Barosi
- Laboratory of Clinical Epidemiology, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy
- Alessandro M. Vannucchi
- Center for Research and Innovation of Myeloproliferative Neoplasms, University of Florence, Italy
- Chiara Paoli
- Center for Research and Innovation of Myeloproliferative Neoplasms, University of Florence, Italy
- Francesco Passamonti
- Ematologia, Dipartimento di Medicina Clinica e Sperimentale, University of Insubria, Varese, Italy
- Bjorn Andreasson
- Internal Medicine, NU Hospital Organization, Uddevalla, Sweden
- Maria L Ferrari
- Biol. Sci., Ospedali Riuniti di Bergamo, Italy
- Alessandro Rambaldi
- Research Foundation (FROM), Hospital Papa Giovanni XXIII, Bergamo, Italy
- Jan Samuelsson
- Department of Internal Medicine, Stockholm South Hospital, Sweden
- Keith Cannon
- Department of Internal Medicine, Mayo Clinic, Scottsdale, AZ, USA
- Gunnar Birgegard
- Department of Hematology, University Hospital, Uppsala, Sweden
- Zhijian Xiao
- MDS and MPN Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
- Zefeng Xu
- MDS and MPN Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
- Yue Zhang
- MDS and MPN Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
- Xiujuan Sun
- MDS and MPN Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
- Junqing Xu
- MDS and MPN Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
- Jean-Jacques Kiladjian
- Clinical Investigation Center, Hospital Saint-Louis, Paris, France
- Peihong Zhang
- Department of Pathology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
- Robert Peter Gale
- Imperial College, London, UK
- Ruben A. Mesa
- Department of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ, USA
- DOI
- https://doi.org/10.3324/haematol.2016.149559
- Journal volume & issue
-
Vol. 102,
no. 1
Abstract
The myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia and myelofibrosis, are distinguished by their debilitating symptom profiles, life-threatening complications and profound impact on quality of life. The role gender plays in the symptomatology of myeloproliferative neoplasms remains under-investigated. In this study we evaluated how gender relates to patients’ characteristics, disease complications and overall symptom expression. A total of 2,006 patients (polycythemia vera=711, essential thrombocythemia=830, myelofibrosis=460, unknown=5) were prospectively evaluated, with patients completing the Myeloproliferative Neoplasm-Symptom Assessment Form and Brief Fatigue Inventory Patient Reported Outcome tools. Information on the individual patients’ characteristics, disease complications and laboratory data was collected. Consistent with known literature, most female patients were more likely to have essential thrombocythemia (48.6% versus 33.0%; P
